Purification and evaluation of anti-inflammatory and antioxidant properties of an apramycin-like compound from Microbacterium barkeri

Biologically active secondary metabolites from actinobacteria are promising sources of therapeutic agents. In this study, an apramycin-like aminoglycoside compound was isolated from Microbacterium barkeri. Thin-layer chromatography of the crude extract yielded six fractions, of which MB4 compound showed the highest antimicrobial activity. So, the compound was purified by HPLC and characterised using FTIR, LC–MS, and 1H and 1³C NMR, confirming its apramycin-like aminoglycoside. Anti-inflammatory activity evaluated by albumin denaturation and human red blood cell membrane stabilisation assays demonstrated significant concentration-dependent effects, with inhibition reaching approximately 95% and 90%, respectively. Antioxidant potential assays showed 14% ABTS scavenging activity, 475 µM ferric reducing power, and 70% DPPH radical scavenging activity at the highest tested concentration. Molecular docking studies against IL-1 and IL-18 receptors revealed binding energies of −6.85 kcal/mol and −7.72 kcal/mol, respectively. These results highlight the pharmacological potential of the apramycin-like aminoglycoside compound from Microbacterium barkeri.